LogicBio Therapeutics, Inc. Quarterly General and Administrative Expense in USD from Q3 2017 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Summary
LogicBio Therapeutics, Inc. quarterly/annual General and Administrative Expense history and growth rate from Q3 2017 to Q3 2022.
  • LogicBio Therapeutics, Inc. General and Administrative Expense for the quarter ending September 30, 2022 was $3.41M, a 19.9% decline year-over-year.
  • LogicBio Therapeutics, Inc. General and Administrative Expense for the twelve months ending September 30, 2022 was $14.4M, a 2.92% decline year-over-year.
  • LogicBio Therapeutics, Inc. annual General and Administrative Expense for 2021 was $16.2M, a 32.9% increase from 2020.
  • LogicBio Therapeutics, Inc. annual General and Administrative Expense for 2020 was $12.2M, a 17.6% increase from 2019.
  • LogicBio Therapeutics, Inc. annual General and Administrative Expense for 2019 was $10.4M, a 51.3% increase from 2018.
General and Administrative Expense, Trailing 12 Months (USD)
General and Administrative Expense, Quarterly (USD)
General and Administrative Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2022 $14.4M $3.41M -$847K -19.9% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $15.3M $3.26M -$506K -13.4% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $15.8M $3.62M -$435K -10.7% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $16.2M $4.15M +$1.35M +48.5% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-04
Q3 2021 $14.9M $4.26M +$1.06M +33% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $13.8M $3.77M +$736K +24.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $13.1M $4.06M +$867K +27.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $12.2M $2.79M -$263K -8.61% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-04
Q3 2020 $12.5M $3.2M +$1.03M +47.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $11.5M $3.03M +$505K +20% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $10.9M $3.19M +$560K +21.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $10.4M $3.05M +$643K +26.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-15
Q3 2019 $9.74M $2.18M +$56K +2.64% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $9.69M $2.52M +$1.11M +78.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $8.58M $2.63M +$1.71M +187% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $6.86M $2.41M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 $2.12M +$1.65M +351% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $1.42M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 $918K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q3 2017 $470K Jul 1, 2017 Sep 30, 2017 10-Q 2018-12-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.